EMMA
Emmaus Life Sciences, Inc.
$0.01
0.00 (-6.84%)
At close · Jul 2
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to the uncertainty of the Company’s ability to meet its current liabilities and operating expenses, there is substantial doubt about the Company’s ability to continue as a going concern for 12 months from the date that these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$761,542
Shares
70,188,263
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.01
Open$0.01
Day$0.01–0.01
52W$0.01–0.02
Avg vol 30d58K
Short int2K · 0.0% float · 1.0d
Short vol14%
Last earningsMay 15, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−8% below
+
Price vs 50-day avg
+8% above
◦
RSI (14)
52 · neutral
+
MACD trend
positive
◦
52-week position
32% · mid-range
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $0 › 200d $0 — 200d above 50d
◦
Institutional flow
No 13F holder data
◦
Insider flow
No net insider activity over 90 days
◦
Short interest
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
No 13F holder history
Fundamentals
Poor
−
Revenue growth
−25% Y/Y
+
Gross margin
93%, expanding
−
EPS growth
−20% Y/Y
−
Free cash flow
$-12.0K
−
Balance sheet
net debt $25.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 15, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−8% below
Bearish
Price vs 50-day avg
+8% above
Bullish
RSI (14)
52 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
32% · mid-range
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 32%
52-wk high $0
vs 200-day avg -8%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EMMA
this stock
Emmaus Life Sciences, Inc.
|
$761,542 | -16.2% | -25.2% | — | 0.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EMMA | +9.0% | +7.9% | -16.2% | +6.9% | -16.2% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +7.6% | +9.2% | -24.2% | +7.1% | -25.4% |